NCT00672802View on ClinicalTrials.gov

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions
Chronic Obstructive Pulmonary DiseaseCOPD
Interventions
DRUG

Ramelteon and Placebo

Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.

Trial Locations (6)

Unknown

Birmingham

Santa Monica

Miami Beach

Winter Park

Louisville

Cincinnati

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00672802 - Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter